Spectropharma

What Spectropharma does

Spectropharma is a Riyadh-headquartered Saudi pharmaceutical company founded in 2019 that develops, manufactures, and commercializes generic and innovative pharmaceutical products across 10+ therapeutic areas including diabetes, cardiovascular, neuroscience, oncology, anti-infectives, uro/nephrology, ENT, and dialysis. Its registered portfolio comprises 40+ products with a pipeline of 300+ products under registration, including molecules such as Vildagliptin (Vtreat), Clopidogrel (Oneclapz), Azacitidine (Dazaspect), and Pemetrexed (Penmate).

The company's core asset is a 54,000+ square meter pharmaceutical manufacturing complex in Sudair Industrial City featuring tablet lines producing up to 186,000 tablets/hour, capsule lines at 50,000 capsules/hour, blister packaging lines at 28,800 cycles/hour, disinfectant solution lines at 10,000 liters/day, dialysis solution lines at 10,000 liters/day, and automated secondary packaging at 48 million units/year. Quality infrastructure is aligned to SFDA-GMP Block A & Block B, ISO 13485, WHO, ISO, and ICH standards, with advanced analytical laboratories using HPLC, Gas Chromatography, FTIR, UV Spectrophotometry, dissolution and disintegration testing, and stability chambers.

The business model is vertically integrated across four revenue streams: (1) direct product sales of registered products across therapeutic categories; (2) contract manufacturing (CMO) for local and international pharmaceutical companies covering production, packaging, and testing under GMP; (3) licensing-in and technology transfer agreements enabling local manufacturing of internationally developed products; and (4) in-house distribution in Saudi Arabia and the wider MENA region, supported by a partner network of 27+ global and regional collaborators including Lupin Global (diabetes) and Amarox Saudi Arabia. The company sells B2B to healthcare providers, hospitals, and government procurement channels, with offices in Riyadh (headquarters) and Jeddah (western region), and leadership including Managing Director and Co-Founder Eng. Abdulaziz Abdullah Al Sheikh, who brings prior global pharmaceutical experience at Johnson & Johnson Medical, Janssen Saudi Arabia, Banaja Group, Lifescan, and Merck Sharp & Dohme.

Name

Spectropharma

Legal name

Spectropharma

Website

https://spectropharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Spectropharma is a Riyadh-based Saudi pharmaceutical manufacturer founded in 2019 that develops, produces, and distributes 40+ generic and innovative medicines across 10+ therapeutic areas, operating a 54,000+ sqm SFDA-GMP-certified facility in Sudair for the Saudi and MENA healthcare markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIAAAA

Primary Care & General Medicine Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAJAB

Specialty Pharmaceutical Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Contract manufacturing
• Drug distribution
• Therapeutic products

Headquarters

HQ city

Riyadh

HQ country

Saudi Arabia

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Manufacturing & Commercialization): Spectropharma manufactures and commercializes generic and innovative pharmaceutical products across 10+ therapeutic areas. Products include oral solid dosages (tablets, capsules), disinfectant solutions, and dialysis solutions. Revenue is generated through direct sales of registered products in Saudi Arabia and regional markets.
2. Contract Manufacturing (CMO): Spectropharma offers contract manufacturing services for local and international companies, covering production, packaging, and testing stages within a strictly regulated GMP environment. This provides recurring revenue from external pharmaceutical companies leveraging Spectropharma's manufacturing capacity.
3. Licensing-in & Technology Transfer: Spectropharma brings in high-quality medicines through licensing-in and technology transfer from international partners for local manufacturing at its Saudi facility, enabling revenue from products developed in partnership.
4. Distribution: Distributing its own and partners' products through in-house distribution capabilities within Saudi Arabia and the regional network, generating revenue through product distribution markups.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Spectropharma develops, manufactures, and commercializes generic and innovative pharmaceutical products across 10+ therapeutic areas (diabetes, cardiovascular, neuroscience, oncology, anti-infectives, uro/nephro, ENT, dialysis) from its GMP-certified manufacturing facility in Sudair Industrial City, Saudi Arabia. The company offers more than 40 registered pharmaceutical and medical device products, including oral solid dosages (tablets, capsules), injections, disinfectant solutions, and dialysis solutions. Beyond its own product portfolio, Spectropharma provides contract manufacturing (CMO) services, licensing-in and technology transfer partnerships, and distribution services for third-party pharmaceutical products.

Product overview

Spectropharma is a Saudi pharmaceutical company offering a diverse portfolio of generic and innovative pharmaceutical products across 10 therapeutic areas (WHO ATC classification), including Diabetes, Cardiovascular, Neuroscience/Psychiatric, Oncology, Anti-infectives, Genitourinary/Urology, Dialysis, ENT, Respiratory, and Vitamins/Supplements. The company's registered product portfolio includes more than 40 pharmaceutical and medical device products. Core products include: Acumen (Atomoxetine for ADHD), Eptop (Topiramate for epilepsy/migraine), Binoven XL (Venlafaxine for depression), Vtreat/Vtreat MET (Vildagliptin for diabetes), Oneclapz/Bistonal/Etimicol/Bosfit/Dabivex (cardiovascular treatments), Dazaspect/Penmate/Spectodoce/Ircan (oncology medications), and Betaquil (Betahistine for Ménière's disease). Beyond manufacturing its own products, Spectropharma offers contract manufacturing services (CMO) for external pharmaceutical companies, along with integrated marketing, distribution, R&D, and product development services.

Differentiator

Problem solved

Functional benefit

Products and services

• Acumen (Atomoxetine) Atomoxetine Hydrochloride capsules for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and above and adults.
• Eptop (Topiramate) Topiramate tablets for migraine prophylaxis in adults and treatment of epilepsy in adults and children over 2 years.
• Binoven XL (Venlafaxine ER) Venlafaxine Extended-Release capsules for Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, OCD, and PTSD.
• Pexoran (Pramipexole) Pramipexole tablets for the treatment of Parkinson's disease and neurological disorders.
• Eletrivaz (Eletriptan) Eletriptan Hydrobromide 40mg tablets for acute treatment of migraine headaches with or without aura in adults.
• Varenapix (Varenicline) Varenicline tablets (0.5mg, 1mg) used as a smoking cessation aid by reducing nicotine cravings.
• Paricalcitol Spectro Paricalcitol injection for secondary hyperparathyroidism in patients with chronic kidney disease (CKD) with or without dialysis.
• Lamsev 800 (Sevelamer Carbonate) Sevelamer Carbonate 800mg tablets for hyperphosphatemia treatment in adult CKD patients on dialysis and phosphorus reduction in non-dialysis CKD patients.
• Hi-Alfa SR 10 (Alfuzosin) Alfuzosin PR 10mg for treatment of benign prostatic hyperplasia (BPH) symptoms including difficulty urinating and urinary retention.
• Tamfrex (Tamsulosin) Tamsulosin Hydrochloride 0.4mg for enlarged prostate BPH and lower urinary tract symptoms, including prevention of acute urinary retention.
• Valgaset 450 (Valganciclovir) Valganciclovir 450mg for CMV eye infections in immunocompromised patients and CMV disease prevention after organ transplant.
• Ircan (Irinotecan) Irinotecan Hydrochloride injection for treatment of advanced or metastatic colon/rectum cancer, used in combination therapy or alone for recurrent disease.
• Dazaspect (Azacitidine) Azacitidine injection for higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
• Penmate (Pemetrexed) Pemetrexed 500mg injection for malignant pleural mesothelioma (with cisplatin) and non-small cell lung cancer treatment.
• Spectodoce (Docetaxel) Docetaxel injection for cancer treatment.
• Vtreat (Vildagliptin) Vildagliptin 50mg tablets for type 2 diabetes management, helping control blood sugar levels in adult patients.
• Vtreat MET (Vildagliptin/Metformin) Vildagliptin/Metformin combination (50/850mg, 50/1000mg) for type 2 diabetes treatment in adults.
• Oneclapz 75 (Clopidogrel) Clopidogrel 75mg film-coated tablets for prevention of blood clots (atherothrombosis) reducing risk of stroke, heart attack, or death.
• Bistonal (Bisoprolol) Bisoprolol Fumarate tablets (2.5mg, 5mg, 10mg) for stable heart failure, hypertension, and angina pectoris.
• Etimicol 10 (Ezetimibe) Ezetimibe 10mg tablets for lowering total cholesterol, LDL cholesterol, and triglycerides while raising HDL cholesterol.
• Dabivex (Dabigatran) Dabigatran capsules (75mg, 110mg, 150mg) for stroke prevention in atrial fibrillation and treatment/prevention of DVT and pulmonary embolism.
• Bosfit (Bosentan) Bosentan tablets (62.5mg, 125mg) for treatment of pulmonary arterial hypertension (PAH) by widening pulmonary arteries.
• Betaquil (Betahistine) Betahistine Dihydrochloride tablets (8mg, 16mg, 24mg) for treatment of Ménière's disease symptoms including vertigo, tinnitus, and hearing loss.
• Contract Manufacturing Services (CMO) Contract manufacturing services for local and international pharmaceutical companies covering production, packaging, and testing stages within a strictly regulated GMP environment.
• Pharmaceutical Distribution Services In-house distribution capabilities covering Saudi Arabia and regional markets for the company's own products and those of its partners.

Quantifiable outcome

• 41 successful drug registrations by 2025 with over 300 products under registration
• +3 more outcomes

Named customers2 records

Segments7 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Lupin GlobalcoreStrategic or Co-development PartnerSpectropharma signed a strategic agreement with Lupin Global for diabetes medicines. This partnership enables Spectropharma to commercialize diabetes treatments within its portfolio, leveraging Lupin's product development capabilities and Spectropharma's local manufacturing and distribution strengths.
• Amarox Saudi ArabiacoreStrategic or Co-development PartnerSpectropharma signed an agreement with Amarox Saudi Arabia at the 'Made in Saudi' Conference. The partnership focuses on product development and distribution collaboration, strengthening Spectropharma's presence in the Saudi pharmaceutical market.
• 27+ Global & Regional Partners (unnamed)coreOthersSpectropharma works with a wide network of 27+ international and regional partners across multiple collaboration models: licensing-in and technology transfer for local manufacturing; contract manufacturing (CMO) for local and international companies; co-development with global and regional R&D labs; distribution partnerships; and sales and marketing collaborations. Partnership principles include technology and knowledge transfer, geographic expansion, supporting joint innovation, and mutual regulatory compliance.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Pharco Pharmaceuticals: Pharco is one of the largest Egyptian pharmaceutical manufacturers, producing generics and branded products across cardiovascular, anti-infectives, CNS, and other primary care areas, with exports across MENA. It is a comparable regional generics manufacturer but is primarily Egypt-anchored rather than directly competing in Saudi.
• EIPICO (Egyptian International Pharmaceutical Industries Company): EIPICO is one of Egypt's largest pharmaceutical manufacturers, producing a wide range of generics across cardiovascular, anti-infectives, CNS, and other therapeutic areas with regional exports. It is a comparable regional generics manufacturer with overlapping therapeutic categories but is Egypt-anchored rather than competing head-to-head in Saudi.
• Neopharma: Neopharma is a UAE-based pharmaceutical manufacturer with GCC-wide distribution and a generics-plus-specialty product mix similar to Spectropharma's. It is a comparable regional manufacturer serving overlapping MENA customers but is primarily anchored in the UAE rather than Saudi Arabia.

Emerging players

• Aurobindo Pharma: Aurobindo is a large Indian generics manufacturer with significant API and finished dosage form capacity and an active presence supplying MENA markets via local partners. It overlaps with Spectropharma as a low-cost generics exporter into Saudi Arabia and as a potential licensing or CMO partner, making it a relevant competitive and ecosystem peer.

Direct peers

• AJA Pharmaceuticals: AJA Pharmaceuticals is a Saudi-based manufacturer of generics and specialty pharmaceutical products, with a portfolio spanning cardiovascular, anti-infectives, and other primary care categories. It is a directly comparable Saudi peer competing for the same hospital, pharmacy, and government procurement contracts.
• Tabuk Pharmaceuticals: Tabuk Pharmaceuticals is a leading Saudi pharma manufacturer with a broad generics and branded portfolio, in-house manufacturing, and active partnerships with global players for technology transfer. It is directly comparable to Spectropharma in being a Saudi-headquartered manufacturer relying on licensing-in and local production to serve the GCC market.
• Saudi Japanese Pharmaceuticals (SJP): Saudi Japanese Pharmaceuticals is a Saudi-based joint-venture pharmaceutical manufacturer producing generics across cardiovascular, anti-infectives, and other primary care areas. It is a directly comparable local Saudi manufacturer competing for the same Saudi hospital, pharmacy, and government channels.
• SPIMACO Addwaa: SPIMACO is the largest Saudi pharmaceutical manufacturer, producing generics and branded drugs across similar therapeutic areas (cardiovascular, diabetes, CNS, antibiotics) and distributing domestically and regionally. It is the most directly comparable Saudi peer to Spectropharma in terms of business model, product mix, and customer base.
• Julphar (Gulf Pharma Industries): Julphar is a UAE-based pharmaceutical manufacturer producing generics across diabetes, cardiovascular, and other primary care categories, with regional distribution across the MENA region. It is a direct regional peer to Spectropharma, operating a similar integrated manufacturing-distribution model targeting GCC and wider MENA customers.

Broad incumbents

• Hikma Pharmaceuticals: Hikma is a Jordan-founded, London-listed multinational that develops, manufactures, and markets a broad portfolio of generics, branded generics, and injectables with deep MENA roots. While much larger and more diversified than Spectropharma, Hikma overlaps directly in generics manufacturing for the Saudi and broader MENA markets and is the regional benchmark incumbent.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/spectropharma
• LinkedInlinkedin.com/company/spectropharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectropharma